Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
The issue proceeds will be used to complete the second part of the clinical study Oncorella-1, which is a phase 1/2 study of safety, tolerability, and anti-tumor efficacy of treatment with ONC175 (Oncorena’s investigational drug product under development) for patients with metastatic clear cell, or papillary renal cell carcinoma, mRCC.
The Vinge team includes Christian Lindhé, Martin Madsen Svanberg and Nathalie Wikman.
